Hims & Hers Acquires US-based Peptide Facility
Hims & Hers Health has acquired a US-based peptide facility in California, strengthening its domestic supply chain capabilities. This acquisition follows previous purchases of 503A and 503B facilities, further verticalizing the company's operations. The move aims to enhance the company's ability to deliver personalized medications and meet growing demand from American consumers.
The peptide facility acquisition positions Hims & Hers to explore future innovations in areas including preventive health, metabolic optimization, cognitive performance, recovery science, and biological resistances. The transaction, which closed in early February, demonstrates the company's commitment to maintaining US-based operations for better control over cost, availability, and quality standards.
Hims & Hers Health ha acquisito un impianto di peptide con sede negli Stati Uniti in California, rafforzando le sue capacità di approvvigionamento nazionale. Questa acquisizione segue precedenti acquisti di impianti 503A e 503B, ulteriormente verticalizzando le operazioni dell'azienda. L'obiettivo è migliorare la capacità dell'azienda di fornire farmaci personalizzati e soddisfare la crescente domanda dei consumatori americani.
L'acquisizione dell'impianto di peptide posiziona Hims & Hers per esplorare future innovazioni in aree come salute preventiva, ottimizzazione metabolica, performance cognitiva, scienza del recupero e resistenze biologiche. La transazione, conclusa all'inizio di febbraio, dimostra l'impegno dell'azienda a mantenere operazioni con sede negli Stati Uniti per un migliore controllo sui costi, disponibilità e standard di qualità.
Hims & Hers Health ha adquirido una instalación de péptidos con sede en EE. UU. en California, fortaleciendo sus capacidades de cadena de suministro nacional. Esta adquisición sigue a compras anteriores de instalaciones 503A y 503B, verticalizando aún más las operaciones de la empresa. El movimiento tiene como objetivo mejorar la capacidad de la empresa para ofrecer medicamentos personalizados y satisfacer la creciente demanda de los consumidores estadounidenses.
La adquisición de la instalación de péptidos posiciona a Hims & Hers para explorar futuras innovaciones en áreas como salud preventiva, optimización metabólica, rendimiento cognitivo, ciencia de la recuperación y resistencias biológicas. La transacción, que se cerró a principios de febrero, demuestra el compromiso de la empresa de mantener operaciones en EE. UU. para un mejor control de costos, disponibilidad y estándares de calidad.
Hims & Hers Health는 미국 캘리포니아에 위치한 펩타이드 시설을 인수하여 국내 공급망 능력을 강화했습니다. 이 인수는 503A 및 503B 시설의 이전 구매에 이어 이루어졌으며, 회사의 운영을 더욱 수직화하고 있습니다. 이 조치는 개인화된 약물을 제공하고 미국 소비자들의 증가하는 수요를 충족시키기 위한 회사의 능력을 향상시키는 것을 목표로 하고 있습니다.
펩타이드 시설의 인수는 Hims & Hers가 예방 건강, 대사 최적화, 인지 성능, 회복 과학 및 생물학적 저항력을 포함한 분야에서 미래 혁신을 탐색할 수 있도록 합니다. 2월 초에 마감된 이 거래는 비용, 가용성 및 품질 기준에 대한 더 나은 통제를 위해 미국 내 운영을 유지하려는 회사의 의지를 보여줍니다.
Hims & Hers Health a acquis une installation de peptides basée aux États-Unis en Californie, renforçant ainsi ses capacités de chaîne d'approvisionnement nationale. Cette acquisition fait suite à des achats précédents d'installations 503A et 503B, verticalisant encore davantage les opérations de l'entreprise. L'objectif de cette démarche est d'améliorer la capacité de l'entreprise à fournir des médicaments personnalisés et à répondre à la demande croissante des consommateurs américains.
L'acquisition de l'installation de peptides positionne Hims & Hers pour explorer de futures innovations dans des domaines tels que la santé préventive, l'optimisation métabolique, la performance cognitive, la science de la récupération et les résistances biologiques. La transaction, qui a été finalisée début février, démontre l'engagement de l'entreprise à maintenir des opérations basées aux États-Unis pour un meilleur contrôle des coûts, de la disponibilité et des normes de qualité.
Hims & Hers Health hat eine in den USA ansässige Peptid-Anlage in Kalifornien erworben, um die nationalen Lieferkettenfähigkeiten zu stärken. Diese Übernahme folgt auf frühere Käufe von 503A- und 503B-Anlagen, wodurch die Betriebsabläufe des Unternehmens weiter vertikalisiert werden. Der Schritt zielt darauf ab, die Fähigkeit des Unternehmens zur Bereitstellung personalisierter Medikamente zu verbessern und die wachsende Nachfrage amerikanischer Verbraucher zu erfüllen.
Der Erwerb der Peptid-Anlage positioniert Hims & Hers, um zukünftige Innovationen in Bereichen wie präventive Gesundheit, metabolische Optimierung, kognitive Leistung, Erholungswissenschaft und biologische Resistenzen zu erkunden. Die Transaktion, die Anfang Februar abgeschlossen wurde, zeigt das Engagement des Unternehmens, US-amerikanische Betriebe aufrechtzuerhalten, um eine bessere Kontrolle über Kosten, Verfügbarkeit und Qualitätsstandards zu gewährleisten.
- Strategic acquisition of peptide facility enhances vertical integration
- Strengthens domestic supply chain control and capabilities
- Enables future expansion into new treatment areas
- Improves operational efficiency and quality control
- Positions company for growth in personalized medicine market
- None.
Insights
The acquisition of a US-based peptide facility represents a strategic masterstroke in HIMS' vertical integration strategy, with three key implications for investors:
Supply Chain Optimization: This acquisition, combined with their existing 503A and 503B facilities, creates a robust, vertically integrated supply chain architecture. This infrastructure significantly reduces dependency on third-party manufacturers, potentially leading to improved gross margins through better cost control and operational efficiencies. The domestic location provides important advantages in quality control, regulatory compliance, and supply chain visibility.
Market Expansion Potential: The peptide facility acquisition positions HIMS at the forefront of several high-growth markets:
- Preventive health and metabolic optimization - estimated to reach
$107 billion globally by 2026 - Cognitive performance solutions - projected to exceed
$15 billion by 2027 - Recovery science and biological resistance treatments - emerging markets with significant growth potential
Competitive Moat: This vertical integration creates significant barriers to entry for competitors. The combination of FDA-compliant manufacturing facilities, direct-to-consumer platform, and now peptide production capabilities positions HIMS uniquely in the personalized medicine space. Few competitors have achieved this level of supply chain control and manufacturing capability.
The timing of this acquisition is particularly strategic, as it coincides with increasing demand for personalized medicine and growing concerns about supply chain resilience. This move strengthens HIMS' ability to maintain consistent product quality while potentially reducing costs - a important advantage in the competitive healthcare platform market.
The acquisition will strengthen the long-term durability of the company’s domestic supply chain, helping to ensure Americans can consistently access personalized medications
The acquisition will strengthen the long-term durability of the company’s domestic supply chain, helping to ensure Americans can consistently access personalized medications. (Photo: Business Wire)
“The future of healthcare must be centered on the customer, which is why our operational structure is built to scale personalized care to more individuals at the highest standard of quality and safety, and with a focus on long-term consistency and availability,” said Melissa Baird, COO of Hims & Hers. “We're building our supply chain to enable more Americans to access care, including personalized treatments designed around their needs. This acquisition is a reflection of our commitment to those goals and our ongoing investment in the customer from start to finish.”
Following the company’s past acquisitions of 503A and 503B facilities, this additional facility deepens the company’s commitment to maintaining operations in
The acquisition closed in early February, and Hims & Hers expects to continue strengthening infrastructure capabilities as demand for personalized treatment continues to grow.
For more information, visit www.hims.com/american-made.
About Hims & Hers Health, Inc
Hims & Hers is the leading health and wellness platform on a mission to help the world feel great through the power of better health. We believe how you feel in your body and mind transforms how you show up in life. That’s why we’re building a future where nothing stands in the way of harnessing this power. Hims & Hers normalizes health & wellness challenges—and innovates on their solutions—to make feeling happy and healthy easy to achieve. No two people are the same, so the company provides access to personalized care designed for results. For more information, please visit www.hims.com and www.forhers.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250221057156/en/
Press Contact
Abby Reisinger
press@forhims.com
Source: Hims & Hers
FAQ
What is the strategic importance of HIMS acquiring the peptide facility?
When did HIMS complete the peptide facility acquisition?
What new treatment areas will HIMS explore through this peptide facility?
How does the peptide facility acquisition fit into HIMS' overall business strategy?
Where is the newly acquired HIMS peptide facility located?
